Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial rationale and design

Circulation: Heart Failure

Volumn 8, Issue 1, 2015, Pages 221-228

  Zakeri, Rosita ^a   Levine, James A ^b   Koepp, Gabriel A ^b   Borlaug, Barry A ^a   Chirinos, Julio A ^c   LeWinter, Martin ^d   Van Buren, Peter ^d   Dvila Romn, Victor G ^e   De Las Fuentes, Lisa ^e   Khazanie, Prateeti ^f   Hernandez, Adrian ^f   Anstrom, Kevin ^f   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRATE; NITRO DERIVATIVE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CROSSOVER PROCEDURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; ENDOTHELIUM; FAINTNESS; HEADACHE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE; HEMODYNAMICS; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EXERCISE TOLERANCE; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; EXERCISE TOLERANCE; HEART FAILURE; HUMANS; NITRO COMPOUNDS; STROKE VOLUME;

EID: 84927712448     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001598     Document Type: Article

References (71)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. doi: 10.1056/ NEJMoa052256.
2. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol. 2003;41:1510-1518.
3. Hoekstra T, Lesman-Leegte I, van Veldhuisen DJ, Sanderman R, Jaarsma T. Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. Eur J Heart Fail. 2011;13:1013-1018. doi: 10.1093/eurjhf/hfr072.
4. Leier CV, Huss P, Magorien RD, Unverferth DV. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure. Circulation. 1983;67:817-822.
5. Elkayam U, Johnson JV, Shotan A, Bokhari S, Solodky A, Canetti M, Wani OR, Karaalp IS. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation. 1999;99:2652-2657.
6. Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and longterm effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med. 1980;69:559-566.
7. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-595. doi: 10.1161/ CIRCHEARTFAILURE.109.930701.
8. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-e479. doi: 10.1161/CIRCULATIONAHA.109.192065.
9. Heart Failure Society of America. Evaluation and management of patients with heart failure and preserved left ventricular ejection fraction. J Card Fail. 2006;12:e80-85.
10. Penicka M, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, Kocka V. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol. 2010;55:1701-1710. doi: 10.1016/j.jacc.2009.11.076.
11. Battock DJ, Levitt PW, Steele PP. Effects of isosorbide dinitrate and nitroglycerin on central circulatory dynamics in coronary artery disease. Am Heart J. 1976;92:455-458.
12. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol. 1996;77:41C-51C.
13. Packer M, Medina N, Yushak M, Lee WH. Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study. Am Heart J. 1985;109:1293-1299.
14. Haber HL, Simek CL, Bergin JD, Sadun A, Gimple LW, Powers ER, Feldman MD. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. J Am Coll Cardiol. 1993;22:251-257.
15. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63:2817-2827.
16. Yaginuma T, Avolio A, O'Rourke M, Nichols W, Morgan JJ, Roy P, Baron D, Branson J, Feneley M. Effect of glyceryl trinitrate on peripheral arteries alters left ventricular hydraulic load in man. Cardiovasc Res. 1986;20:153-160.
17. Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension. 2003;41:297-301.
18. Chirinos JA, Segers P, Gillebert TC, Gupta AK, De Buyzere ML, De Bacquer D, St John-Sutton M, Rietzschel ER; Asklepios Investigators. Arterial properties as determinants of time-varying myocardial stress in humans. Hypertension. 2012;60:64-70. doi: 10.1161/ HYPERTENSIONAHA.112.190710.
19. Gillebert TC, Lew WY. Influence of systolic pressure profile on rate of left ventricular pressure fall. Am J Physiol. 1991;261:H805-H813.
20. Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol. 1998;32:1221-1227.
21. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714-720.
22. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442-451. doi: 10.1016/j. jacc.2011.09.062.
23. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845-854. doi: 10.1016/j.jacc.2010.03.077.
24. Ludbrook PA, Byrne JD, Kurnik PB, McKnight RC. Influence of reduction of preload and afterload by nitroglycerin on left ventricular diastolic pressure-volume relations and relaxation in man. Circulation. 1977;56:937-943.
25. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006-2013. doi: 10.1161/CIRCULATIONAHA.110.954388.
26. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739-749.
27. Schwarz M, Katz SD, Demopoulos L, Hirsch H, Yuen JL, Jondeau G, LeJemtel TH. Enhancement of endothelium-dependent vasodilation by low-dose nitroglycerin in patients with congestive heart failure. Circulation. 1994;89:1609-1614.
28. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49:1289-1295. doi: 10.1016/j.jacc.2006.10.074.
29. Oelze M, Knorr M, Kröller-Schön S, Kossmann S, Gottschlich A, Rümmler R, Schuff A, Daub S, Doppler C, Kleinert H, Gori T, Daiber A, Münzel T. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J. 2013;34:3206-3216. doi: 10.1093/ eurheartj/ehs100.
30. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263-271. doi: 10.1016/j. jacc.2013.02.092.
31. van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839. doi: 10.1161/ CIRCULATIONAHA.111.076075.
32. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268-1277. doi: 10.1001/jama.2013.2024.
33. Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87-94. doi: 10.1161/CIRCRESAHA.108.184408.
34. Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011;123:2132-2144. doi: 10.1161/CIRCULATIONAHA.110.981407.
35. Gupta D, Georgiopoulou VV, Kalogeropoulos AP, Marti CN, Yancy CW, Gheorghiade M, Fonarow GC, Konstam MA, Butler J. Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. JACC Heart Fail. 2013;1:183-191. doi: 10.1016/j.jchf.2013.03.003.
36. Elkayam U, Roth A, Mehra A, Ostrzega E, Shotan A, Kulick D, Jamison M, Johnston JV, Rahimtoola SH. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation. 1991;84:2040-2048.
37. Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, Watts LE, Garutti RJ, Ferraresi R, Casareto R. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72:1249-1256.
38. Gunasekara NS, Noble S. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris. Drugs. 1999;57:261-277.
39. Coyne KS, Allen JK. Assessment of functional status in patients with cardiac disease. Heart Lung. 1998;27:263-273.
40. Jehn M, Schmidt-Trucksäss A, Hanssen H, Schuster T, Halle M, Koehler F. Association of physical activity and prognostic parameters in elderly patients with heart failure. J Aging Phys Act. 2011;19:1-15.
41. Kadhiresan VA, Pastore J, Auricchio A, Sack S, Doelger A, Girouard S, Spinelli JC; PATH-CHF Study Group. Pacing therapies in congestive heart failure. A novel method-the activity log index-for monitoring physical activity of patients with heart failure. Am J Cardiol. 2002;89:1435-1437.
42. Jehn M, Schmidt-Trucksäess A, Schuster T, Hanssen H, Weis M, Halle M, Koehler F. Accelerometer-based quantification of 6-minute walk test performance in patients with chronic heart failure: applicability in telemedicine. J Card Fail. 2009;15:334-340. doi: 10.1016/j.cardfail.2008.11.011.
43. van den Berg-Emons R, Balk A, Bussmann H, Stam H. Does aerobic training lead to a more active lifestyle and improved quality of life in patients with chronic heart failure? Eur J Heart Fail. 2004;6:95-100. doi: 10.1016/j.ejheart.2003.10.005.
44. Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG, Paul R. Analysis of daily activity data from implanted cardiac defibrillators: the minimum clinically important difference and relationship to mortality/life expectancy. World J Cardiovasc Dis. 2012;2:129-135.
45. Conraads VM, Spruit MA, Braunschweig F, Cowie MR, Tavazzi L, Borggrefe M, Hill MR, Jacobs S, Gerritse B, van Veldhuisen DJ. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure. Circ Heart Fail. 2014;7:279-287. doi: 10.1161/ CIRCHEARTFAILURE.113.000883.
46. Kawabata M, Fantoni C, Regoli F, Raffa S, Pastori F, Fratini S, Prentice J, Klein HU, Auricchio A. Activity monitoring in heart failure patients with cardiac resynchronization therapy. Circ J. 2007;71:1885-1892.
47. Gilliam FR 3rd, Kaplan AJ, Black J, Chase KJ, Mullin CM. Changes in heart rate variability, quality of life, and activity in cardiac resynchronization therapy patients: results of the HF-HRV registry. Pacing Clin Electrophysiol. 2007;30:56-64. doi: 10.1111/j.1540-8159.2007.00582.x.
48. Lores V, García-Río F, Rojo B, Alcolea S, Mediano O. Recording the daily physical activity of COPD patients with an accelerometer: an analysis of agreement and repeatability. Arch Bronconeumol. 2006;42:627-632.
49. Hecht A, Ma S, Porszasz J, Casaburi R; COPD Clinical Research Network. Methodology for using long-term accelerometry monitoring to describe daily activity patterns in COPD. COPD. 2009;6:121-129. doi: 10.1080/15412550902755044.
50. Jehn M, Schmidt-Trucksäss A, Meyer A, Schindler C, Tamm M, Stolz D. Association of daily physical activity volume and intensity with COPD severity. Respir Med. 2011;105:1846-1852. doi: 10.1016/j. rmed.2011.07.003.
51. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, Smith C, Man WD, Tal-Singer R, Edwards LD, Calverley PM, Magnussen H, Polkey MI, Wouters EF. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106:522-530. doi: 10.1016/j. rmed.2011.10.022.
52. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Löffler M, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B; Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781-791. doi: 10.1001/ jama.2013.905.
53. Wisenberg G, Roks C, Nichol P, Goddard MD. Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris. Am J Cardiol. 1989;64:569-576.
54. Svendsen JH, Aldershvile J, Abildgaard U, Amtorp O. Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to betablocking agents in patients with stable angina pectoris. J Cardiovasc Pharmacol. 1989;14:358-363.
55. Rinaldi CA, Linka AZ, Masani ND, Avery PG, Jones E, Saunders H, Hall RJ. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning. Circulation. 1998;98:749-756.
56. Matthew CE. Calibration of accelerometer output for adults. Med Sci Sports Exerc. 2005;37:S512-S522.
57. Pizzulli L, Hagendorff A, Zirbes M, Fehske W, Ewig S, Jung W, Lüderitz B. Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am Heart J. 1996;131:342-349.
58. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, doubleblind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol. 1998;32:1194-1200.
59. Liuni A, Luca MC, Di Stolfo G, Uxa A, Mariani JA, Gori T, Parker JD. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans. J Am Coll Cardiol. 2011;57:93-98. doi: 10.1016/j.jacc.2010.07.037.
60. Münzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470. doi: 10.1172/JCI118935.
61. Catellier DJ, Hannan PJ, Murray DM, Addy CL, Conway TL, Yang S, Rice JC. Imputation of missing data when measuring physical activity by accelerometry. Med Sci Sports Exerc. 2005;37:S555-562.
62. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and presentation of crossover trials. Trials. 2009;10:27. doi: 10.1186/1745-6215-10-27.
63. Senn S. Cross-Over Trials in Clinical Research, 2nd ed. Chichester, West Sussex, England: John Wiley & Sons Ltd; 2002.
64. Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail. 2013;6:862-868. doi: 10.1161/ CIRCHEARTFAILURE.113.000394.
65. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS; Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707-715. doi: 10.1016/j.ahj.2004.12.010.
66. Flynn KE, Lin L, Moe GW, Howlett JG, Fine LJ, Spertus JA, McConnell TR, Piña IL, Weinfurt KP. Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. Am Heart J. 2012;163:88-94.e3. doi: 10.1016/j. ahj.2011.09.027.
67. O'Keeffe ST, Lye M, Donnellan C, Carmichael DN. Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart. 1998;80:377-382.
68. Handler CE, Sullivan ID. Double-blind randomised crossover trial comparing isosorbide dinitrate cream and oral sustained-release tablets in patients with angina pectoris. Int J Cardiol. 1985;7:149-157.
69. Uusitalo A. Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving betablockers. Drugs. 1987;33(suppl 4):111-117.
70. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520-531. doi: 10.1056/NEJM199802193380807.
71. Thompson WG, Kuhle CL, Koepp GA, McCrady-Spitzer SK, Levine JA. "Go4Life" exercise counseling, accelerometer feedback, and activity levels in older people. Arch Gerontol Geriatr. 2014;58:314-319. doi: 10.1016/j.archger.2014.01.004.